Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages
Abstract
Previous studies of prostate cancer autoantibodies have largely focused on diagnostic applications. So far, there have been no reports attempting to more comprehensively profile the landscape of prostate cancer-associated antibodies. Specifically, it is unknown whether the quantity of antibodies or the types of proteins recognized change with disease progression.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2020
- Source ID
- 10.1136/jitc-2020-001510
Entities
People
- Christopher A. Maher
- Douglas McNeel
- Hemanth K. Potluri
- Jin Zhang
- Michael A. Newton
- Peter S Nelson
- Tun Lee Ng
Organizations
- Congressionally Directed Medical Research Programs
- National Cancer Institute
- National Institutes of Health